摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-[(2-methyl-4-quinolinyl)methoxy]benzoyl chloride HCl salt | 362707-20-8

中文名称
——
中文别名
——
英文名称
4-[(2-methyl-4-quinolinyl)methoxy]benzoyl chloride HCl salt
英文别名
4-((2-Methylquinolin-4-yl)methoxy)benzoyl chloride hydrochloride;4-[(2-methylquinolin-4-yl)methoxy]benzoyl chloride;hydrochloride
4-[(2-methyl-4-quinolinyl)methoxy]benzoyl chloride HCl salt化学式
CAS
362707-20-8
化学式
C18H14ClNO2*ClH
mdl
——
分子量
348.229
InChiKey
CGTVCROWIXWEBV-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.92
  • 重原子数:
    23
  • 可旋转键数:
    4
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.11
  • 拓扑面积:
    39.2
  • 氢给体数:
    1
  • 氢受体数:
    3

反应信息

  • 作为反应物:
    描述:
    4-[(2-methyl-4-quinolinyl)methoxy]benzoyl chloride HCl salt4-(dicyanomethylene)-2-methyl-6-(p-dimethylaminostyryl)-4H-pyran碳酸氢钠 作用下, 以11%的产率得到(trans)-N-[(2,4-dioxo-1,3-diazaspiro[4.5]dec-6-yl)methyl]-4-[(2-methyl-4-quinolinyl)methoxy]-benzamide
    参考文献:
    名称:
    Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE)
    摘要:
    本申请描述了具有以下式(I)的新型咪唑啉衍生物:1或其药用可接受的盐或前药形式,其中A、B、R1、R2、R3、R4、R5、R6、R7、R11和n在本说明书中有定义,这些衍生物可用作基质金属蛋白酶(MMP)、TNF-α转化酶(TACE)、聚集素酶的抑制剂,或其组合。
    公开号:
    US20030130273A1
点击查看最新优质反应信息

文献信息

  • Beta-Amino-Acid derivatives as inhibitors of matrix metalloproteases and TNF-Alpha
    申请人:——
    公开号:US20020013341A1
    公开(公告)日:2002-01-31
    The present application describes novel &bgr;-amino acid derivatives of formula I: 1 or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, X, Z, U a , X a , Y a , Z a , R 1 , R 2 , R 3 , R 4 , and R 4a are defined in the present specification, which are useful as metalloprotease and/or as TNF-&agr; inhibitors.
    本申请描述了式I的新型β-氨基酸生物: 1 或其药用可接受的盐或前药形式,其中A、X、Z、U a 、X a 、Y a 、Z a 、R 1 、R 2 、R 3 、R 4 和R 4a 在本规范中有定义,这些衍生物可用作蛋白酶和/或TNF-α抑制剂
  • Beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha
    申请人:——
    公开号:US20040072802A1
    公开(公告)日:2004-04-15
    The present application describes novel &bgr;-amino acid derivatives of formula I: 1 or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, X, Z, U a , X a , Y a , Z a , R 1 , R 2 , R 3 , R 4 , and R 4a are defined in the present specification, which are useful as metalloprotease and/or as TNF-&agr; inhibitors.
    本申请描述了式I的新颖β-氨基酸生物:1或其药用可接受的盐或前药形式,其中A、X、Z、Ua、Xa、Ya、Za、R1、R2、R3、R4和R4a在本规范中有定义,这些衍生物可用作蛋白酶和/或TNF-α抑制剂
  • [EN] HYDANTION DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES<br/>[FR] DERIVES D'HYDANTOINE UTILISES COMME INHIBITEURS DES METALLOPROTEINASES MATRICIELLES
    申请人:BRISTOL MYERS SQUIBB CO
    公开号:WO2002096426A1
    公开(公告)日:2002-12-05
    The present application describes novel hydantoin derivatives of formula (I), or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, B, R?1, R2, R3, R4, R5, R6, R7, R11¿, and n are defined in the present specification, which are useful as inhibitors of matrix metallproteinases (MMP), TNF-α converting enzyme (TACE), aggrecanase, or a combination thereof.
    本申请描述了式(I)的新型嘧啶生物,或其药学上可接受的盐或前药形式,其中A,B,R?1,R2,R3,R4,R5,R6,R7,R11¿和n在本说明书中有定义,它们可用作基质蛋白酶MMP),TNF-α转化酶TACE),聚集素酶或其组合的抑制剂
  • Triazolone and triazolethione derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme
    申请人:——
    公开号:US20040116491A1
    公开(公告)日:2004-06-17
    The present application describes novel hydantoin derivatives of formula (I): 1 or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, L, and R 11 are defined in the present specification, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-&agr; converting enzyme (TACE), aggrecanase, or a combination thereof.
    本申请描述了式 (I) 的新型海因生物: 1 或其药学上可接受的盐或原药形式,其中 A、L 和 R 11 可用作基质蛋白酶 (MMP)、TNF-&agr; 转换酶 (TACE)、凝集素酶或其组合的抑制剂
  • BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEASES AND TNF-ALPHA
    申请人:Bristol-Myers Squibb Pharma Company
    公开号:EP1263756A2
    公开(公告)日:2002-12-11
查看更多